Dataset Information


Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.

ABSTRACT: RNA-guided CRISPR/Cas9 systems can be designed to mutate or excise the integrated HIV genome from latently infected cells and have therefore been proposed as a curative approach for HIV. However, most studies to date have focused on molecular clones with ideal target site recognition and do not account for target site variability observed within and between patients. For clinical success and broad applicability, guide RNA (gRNA) selection must account for circulating strain diversity and incorporate the within-host diversity of HIV.We identified a set of gRNAs targeting HIV LTR, gag, and pol using publicly available sequences for these genes and ranked gRNAs according to global conservation across HIV-1 group M and within subtypes A-C. By considering paired and triplet combinations of gRNAs, we found triplet sets of target sites such that at least one of the gRNAs in the set was present in over 98% of all globally available sequences. We then selected 59 gRNAs from our list of highly conserved LTR target sites and evaluated in vitro activity using a loss-of-function LTR-GFP fusion reporter. We achieved efficient GFP knockdown with multiple gRNAs and found clustering of highly active gRNA target sites near the middle of the LTR. Using published deep-sequence data from HIV-infected patients, we found that globally conserved sites also had greater within-host target conservation. Lastly, we developed a mathematical model based on varying distributions of within-host HIV sequence diversity and enzyme efficacy. We used the model to estimate the number of doses required to deplete the latent reservoir and achieve functional cure thresholds. Our modeling results highlight the importance of within-host target site conservation. While increased doses may overcome low target cleavage efficiency, inadequate targeting of rare strains is predicted to lead to rebound upon cART cessation even with many doses.Target site selection must account for global and within host viral genetic diversity. Globally conserved target sites are good starting points for design, but multiplexing is essential for depleting quasispecies and preventing viral load rebound upon therapy cessation.

SUBMITTER: Roychoudhury P 

PROVIDER: S-EPMC6040082 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4851589 | BioStudies
2018-01-01 | S-EPMC6553478 | BioStudies
2019-01-01 | S-EPMC6864089 | BioStudies
2020-01-01 | S-EPMC7452136 | BioStudies
2018-01-01 | S-EPMC6238604 | BioStudies
2017-01-01 | S-EPMC5663707 | BioStudies
2019-01-01 | S-EPMC6466431 | BioStudies
2013-01-01 | S-EPMC3587049 | BioStudies
1000-01-01 | S-EPMC5958087 | BioStudies
2019-01-01 | S-EPMC6836449 | BioStudies